Aldeyra Therapeutics Inc (ALDX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access ALDX Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Aldeyra Therapeutics Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Available-for-sale Securities, Debt Securities, Current MA0.00
Cash & Short-term Investments0.00
Other Current Assets43.85
Prepaid Expense And Other Assets Current3.53
Total Current Assets47.38
Equipment/Property/Plant Net0.02
Other Assets, Noncurrent0.14
Cash And Money Market Funds65.00
Total Assets47.54
Liabilities
Accounts Payable, Current AC0.14
Accrued Liabilities, Current AC3.37
Long-term Debt, Current Maturities LO0.00
Deferred Revenue, Current DE0.00
Total Current Liabilities9.66
Total Long-term Debt0.00
Deferred Long-term Liability Charges DE6.00
Other liabilities, Noncurrent0.14
OperatingLeaseLiabilityNoncurrent-
Operating Lease Liability Current0.21
Total Liabilities9.66
Stockholders' Equity
Common Stock Value0.06
Additional Paid In Capital Common Stock530.69
Retained Earnings / Accumulated Deficit-492.86
Other Equity0.00
Common Stockholder's Equity37.89
Total Stockholder's Equity37.89
Liabilities & Stockholder's Equity47.54
4 historic quarters locked

Sign in to unlock the full Aldeyra Therapeutics Inc balance sheet history.

About Aldeyra Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001341235-26-000010

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.